History

 

When Michael Zang-Gandor and Dr. Christine Gandor founded EUGENEX Biotechnologies GmbH in 1999, they utilized 10+ years of experience and skills in mammalian cell culture, molecular genetics, and gene expression. The EUGENEX team established the first expression system with a unique, animal component-free technology platform that satisfies all regulatory requirements.

 

EUGENEX has always worked independently from outside investors. This affords the company the flexibility to take on ambitious projects, pivot when necessary and follow their own convictions. Within two decades EUGENEX Biotechnologies has become a major provider of cell lines and processes for the biopharmaceutical industry.

 Old bioreactor from the early days of EUGENEX

 EUGENEX – A Success Story

2021 - Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process
     
2020 - EUGENEX develops a novel therapeutic agent against Covid-19 (Coronavirus SARS-CoV-2)
     
2019 -
10 biosimilars derived from EUGENEX’s cell lines are on the market
  - Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process
     
2018 - 20th anniversary of EUGENEX Biotechnologies
    Food and Drug Administration (FDA) approval of a biosimilar derived from a EUGENEX Cell Line/Process
     
2017 - Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process
     
2016  Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process
     
2015  Launch of a monoclonal antibody derived from a EUGENEX Cell Line/Process
     
2014  Launch of a glycosylated cytokine derived from a EUGENEX Cell Line/Process
     
2013  Launch of a glycosylated cytokine derived from a EUGENEX Cell Line/Process
     
2008 First biosimilar derived from a EUGENEX Cell Line/Process reaches the non-regulated market
     
2007  First biosimilar derived from a EUGENEX Cell Line/Process reaches the European market 
     
2006  Winner of an international innovation prize with the project: "Biological Coating for Implants"
     
2005  European Medicines Agency (EMA) approves a biosimilar derived from a EUGENEX Cell Line/Process
     
2004  First tech transfer of USP for biosimilar production 
  Winner of an international innovation prize with the project: "Detection and Validation System of New Medically Effective Substances" 
     
2003   Winner of an international innovation prize with the project "Development and Production System of High-Quality Recombinant Proteins" 
     
2000  Relocation of EUGENEX Biotechnologies to larger premises in Taegerwilen, Lake of Constance, Switzerland 
     
1999  Development of first commercial production cell line 
  Establishment of EUGENEX platform for cell line development 
  Establishment of EUGENEX Biotechnologies GmbH 
     
1998  Establishment of EUGENEX Biotechnologies laboratories in Matzingen, Switzerland 

 

 

 Michael Zang-Gandor in the early days of the company